Vimarsana
Biggest News Aggregation in the World

Page 14 - Refractive Surgery News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Refractive Surgery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Refractive Surgery Today - Breaking & Trending Today

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis - Vimarsana News

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the...

New Study Shows ZEPTO Precision Pulse Capsulotomy Safeguards Endothelial Cells as Effectively as Manual Capsulorhexis - Vimarsana News

New Study Shows ZEPTO Precision Pulse Capsulotomy Safeguards Endothelial Cells as Effectively as Manual Capsulorhexis

/PRNewswire/ -- Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO IOL Positioning Systemâ„¢, today announced that a new...

Pioneer of Refractive Surgery to Join Advisory Board of Evolution Optiks - Vimarsana News

Pioneer of Refractive Surgery to Join Advisory Board of Evolution Optiks

/PRNewswire/ -- Evolution Optiks Limited announced today that Prof. Dr. Thomas Neuhann had joined the ranks of experts serving on the Advisory Board of the...

Ophthalmologist job with Singapore National Eye Centre - Vimarsana News

Ophthalmologist job with Singapore National Eye Centre

Ophthalmologist job in Singapore (SG) with Singapore National Eye Centre. Apply Today.

Source: bmj.com
Are ophthalmology procedures shifting out of ASCs? - Vimarsana News

Are ophthalmology procedures shifting out of ASCs?

A new study conducted by iOR Partners has found that office-based lens surgery is as safe as lens surgery at other sites. The study evaluated over 18,000 consec